The Evolution of Consent in Biomedical AI: Ensuring Privacy and Equity

By Staff Writer

July 4, 2024

Introduction

The evolution of consent in biomedical AI is crucial in maintaining privacy and equity. As AI technologies advance, traditional consent models must adapt to safeguard individuals’ privacy and promote inclusive healthcare. This article examines the complexities of consent in the context of biomedical AI as published in the New England Journal of Medicine (NEJM), highlighting the need for updated frameworks that address modern challenges.

Can Consent Protect Privacy?

Informed consent, as conceived in the 1970s, was designed to protect individuals’ privacy by allowing them to control their data. However, in today’s data-intensive environment, this approach is increasingly ineffective. Algorithms now draw inferences from data, making it possible to infer information about non-consenting individuals. This systemic privacy loss necessitates a reevaluation of consent’s role in protecting privacy.

Consent’s Disparate Impact

Consent rules, although neutral, can have discriminatory impacts. Vulnerable groups, such as migrants or individuals in states with restrictive reproductive laws, are more likely to opt out of data sharing. This underinclusion in AI training data can lead to tools that do not work effectively for these groups. Thus, consent rights, once a bioethical triumph, now risk undermining equity and safety in biomedical AI.

Diminished Public Voice

Consent rights, intended to empower individuals, have fragmented the public’s voice in privacy policy. Data handlers often cater to the least demanding consenters, ignoring broader societal privacy concerns. This individualistic approach contrasts with collective bargaining in labour rights, where collective action amplifies workers’ voices. Current research regulations lack mechanisms for collective public action to influence data use policies.

Failure to Minimise Privacy Risks

Modern research regulations require ethical review boards to minimise risks to human subjects. However, these boards often lack the expertise to manage privacy risks effectively. Consequently, informed consent is sometimes treated as a formality rather than a robust privacy safeguard. This approach, prioritising expediency over trust, risks public backlash that could hinder scientific progress.

Consent and Reciprocity

The UK’s Care.Data project illustrates the pitfalls of ignoring public trust in data initiatives. Despite legal oversight, public backlash led to its termination. Postmortem studies identified reciprocity, nonexploitation, and service of the public good as key principles for public buy-in. Ethical data handling and clear communication with the public are essential for maintaining trust and ensuring the success of biomedical AI projects.

Reciprocity and Open Data Sharing

Open data sharing can coexist with reciprocity if privacy and data use policies are clear and inclusive. Agencies like the National Institutes of Health must establish transparent policies and involve the public in decision-making processes. Biomedical AI, as a collective endeavour, benefits from broad public participation, which top-down policy-setting cannot achieve.

Is Co-Creation of Consent Realistic?

Engaging research participants in co-creating consent is feasible with AI-powered digital tools. Platforms like vTaiwan demonstrate how large groups can deliberate and reach consensus on complex issues. Biomedical AI requires similar tools to involve patients in shaping consent standards, thereby enhancing democratic legitimacy and trust in research.

AI-Powered Bioethics

AI-powered digital tools enable large-scale public engagement in policy-making. Examples like the CrowdLaw Catalog show that governments and institutions can use these tools to gather public input. Biomedical AI must adopt similar approaches to develop ethical frameworks that reflect public values and concerns.

Conclusion

The evolution of consent in biomedical AI is essential for ensuring privacy and equity in healthcare. Traditional consent models must adapt to address modern challenges, involving the public in shaping data use policies. AI-powered bioethics can facilitate this process, fostering trust and inclusivity in biomedical research.

Reference url

Recent Posts

datopotamab deruxtecan approval
   

FDA Grants Datopotamab Deruxtecan Approval for HR-Positive Breast Cancer Treatment

💡 *What does the FDA’s latest approval mean for patients with advanced breast cancer?*
Datopotamab deruxtecan (Datroway) has just been approved for treating unresectable or metastatic HR-positive, HER2-negative breast cancer, offering new hope for patients who have already undergone multiple therapies. This breakthrough, stemming from the TROPION-Breast01 trial, showcases significant improvements in progression-free survival rates—a vital advancement in cancer care.

Curious about the implications of this treatment for both healthcare providers and patients? Dive into the full article to learn more!

#SyenzaNews #oncology #HealthcareInnovation

surrogate endpoints guidance
          

Surrogate Endpoints Guidance: New International Report Enhances HTA Practices

🔍 Are surrogate endpoints the key to shaping the future of health technology assessment?

A new report led by NICE reveals standardized guidance for using surrogate endpoints in health economic models, providing clarity and validation tools for HTA decisions. This collaborative effort across multiple global agencies aims to enhance predictions of long-term health benefits from short-term data.

Jump into the article to explore these impactful insights and learn how this guidance is set to improve health technology evaluations!

#SyenzaNews #HealthEconomics #HealthcareInnovation

cervical cancer prevention
    

Cervical Cancer Prevention Strategies: Insights from South African

🌍 Did you know South African women living with HIV face a significantly higher risk of cervical cancer?

Our latest article looks into the perspectives of women and their partners regarding innovative cervical cancer prevention strategies, including the acceptability of the intravaginal 5-fluorouracil (5FU) treatment. It highlights the critical role of education and counseling in improving screening uptake and treatment adherence.

Explore how we can enhance cervical health for vulnerable populations!

#SyenzaNews #globalhealth #oncology #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.